JP2011529033A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529033A5
JP2011529033A5 JP2011519189A JP2011519189A JP2011529033A5 JP 2011529033 A5 JP2011529033 A5 JP 2011529033A5 JP 2011519189 A JP2011519189 A JP 2011519189A JP 2011519189 A JP2011519189 A JP 2011519189A JP 2011529033 A5 JP2011529033 A5 JP 2011529033A5
Authority
JP
Japan
Prior art keywords
cancer
pyridin
mol
added
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011519189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529033A (ja
JP5480261B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059605 external-priority patent/WO2010010191A1/en
Publication of JP2011529033A publication Critical patent/JP2011529033A/ja
Publication of JP2011529033A5 publication Critical patent/JP2011529033A5/ja
Application granted granted Critical
Publication of JP5480261B2 publication Critical patent/JP5480261B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011519189A 2008-07-25 2009-07-24 変性及び炎症性疾患の治療に有用な新規化合物 Active JP5480261B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13592008P 2008-07-25 2008-07-25
US61/135,920 2008-07-25
US22068509P 2009-06-26 2009-06-26
US61/220,685 2009-06-26
PCT/EP2009/059605 WO2010010191A1 (en) 2008-07-25 2009-07-24 Novel compounds useful for the treatment of degenerative and inflammatory diseases.

Publications (3)

Publication Number Publication Date
JP2011529033A JP2011529033A (ja) 2011-12-01
JP2011529033A5 true JP2011529033A5 (enExample) 2012-09-06
JP5480261B2 JP5480261B2 (ja) 2014-04-23

Family

ID=41021059

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011519188A Active JP5559168B2 (ja) 2008-07-25 2009-07-24 変性及び炎症性疾患の治療に有用な新規化合物
JP2011519189A Active JP5480261B2 (ja) 2008-07-25 2009-07-24 変性及び炎症性疾患の治療に有用な新規化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011519188A Active JP5559168B2 (ja) 2008-07-25 2009-07-24 変性及び炎症性疾患の治療に有用な新規化合物

Country Status (35)

Country Link
US (5) US8853240B2 (enExample)
EP (2) EP2361251B1 (enExample)
JP (2) JP5559168B2 (enExample)
KR (2) KR101711911B1 (enExample)
CN (2) CN102105471B (enExample)
AR (1) AR072875A1 (enExample)
AU (2) AU2009273143B2 (enExample)
BR (2) BRPI0916862B8 (enExample)
CA (2) CA2730757A1 (enExample)
CL (1) CL2009001637A1 (enExample)
CO (1) CO6361925A2 (enExample)
CR (1) CR20110092A (enExample)
CY (2) CY1113945T1 (enExample)
DK (2) DK2361251T3 (enExample)
DO (1) DOP2011000022A (enExample)
EA (2) EA018587B1 (enExample)
ES (2) ES2406691T3 (enExample)
HR (2) HRP20140681T1 (enExample)
IL (2) IL210262A (enExample)
JO (1) JO3041B1 (enExample)
MA (1) MA32551B1 (enExample)
ME (1) ME02046B (enExample)
MX (2) MX2011000756A (enExample)
MY (1) MY157615A (enExample)
NZ (1) NZ590646A (enExample)
PE (1) PE20100152A1 (enExample)
PL (2) PL2346864T3 (enExample)
PT (2) PT2361251E (enExample)
RS (2) RS53406B (enExample)
SI (2) SI2361251T1 (enExample)
SM (2) SMT201300051B (enExample)
TW (1) TWI447118B (enExample)
UY (1) UY32006A (enExample)
WO (2) WO2010010191A1 (enExample)
ZA (2) ZA201100396B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
US20100331222A1 (en) * 2009-06-26 2010-12-30 Basf Se Process for producing cellulose beads from solutions of cellulose in ionic liquid
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2566333A4 (en) * 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CN103965114B (zh) * 2013-01-28 2016-01-06 苏州泽璟生物制药有限公司 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
CN105339370B (zh) * 2013-06-19 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎症性疾病的化合物和及其药物组合物
LT3077395T (lt) 2013-12-05 2018-02-12 Pfizer Inc. Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai
CA2934251C (en) 2013-12-20 2024-01-02 3-V Biosciences, Inc. A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
WO2016119700A1 (en) 2015-01-28 2016-08-04 Jn Therapeutics Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
KR20170134750A (ko) * 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
EP3290418B1 (en) * 2015-04-29 2019-05-15 Wuxi Fortune Pharmaceutical Co., Ltd Janus kinase (jak) inhibitors
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN108349974B (zh) * 2016-02-02 2021-04-30 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
EP3492468B1 (en) * 2016-07-26 2022-02-23 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
TWI752098B (zh) * 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
SG11201902882UA (en) * 2016-10-26 2019-05-30 Janssen Pharmaceutica Nv Fused azaheterocyclic compounds and their use as ampa receptor modulators
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
CN108341814B (zh) * 2017-01-23 2021-09-03 上海翔锦生物科技有限公司 Jak激酶抑制剂及其应用
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
FI3595667T3 (fi) 2017-03-14 2024-01-12 Galapagos Nv Farmaseuttiset koostumukset, joihin sisältyy jak-estäjän tausta
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
CN111479810B (zh) * 2018-01-31 2022-11-22 珠海联邦制药股份有限公司 Jak抑制剂及其应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
EP3758700B1 (en) 2018-02-28 2024-07-31 University of Southern California Compositions for modulating inflammatory and degenerative disorders
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
ES2973331T3 (es) * 2018-08-23 2024-06-19 Zhuhai United Laboratories Co Ltd Compuesto de [1,2,4]triazolo[1,5-a]piridina como inhibidor de JAK y aplicación del mismo
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US12509455B2 (en) 2018-11-07 2025-12-30 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル － ゲル テクノロジーズ リミテッド Ｅｇｆｒ阻害剤を含む組成物による皮膚障害の治療
TW202116754A (zh) 2019-07-11 2021-05-01 美商Ｅ 斯蓋普生物股份有限公司 作為ｌｒｒｋ２抑制劑之吲唑及氮雜吲唑
CN111892592B (zh) * 2019-08-06 2023-09-19 江苏柯菲平医药股份有限公司 Jak激酶抑制剂及其用途
CA3156828A1 (en) 2019-10-03 2021-04-08 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
AU2020428591B2 (en) * 2020-02-13 2024-05-23 Zhuhai United Laboratories Co., Ltd. Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
WO2021168375A1 (en) 2020-02-20 2021-08-26 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
WO2021164786A1 (zh) * 2020-02-21 2021-08-26 珠海联邦制药股份有限公司 Jak抑制剂的晶型及其应用
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
CN111617318B (zh) * 2020-05-26 2021-12-10 南京市儿童医院 可注射型儿童骺板再生水凝胶的制备方法
CN114075188A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 芳香杂环酰胺类化合物及其制备方法和医药用途
CN114075189A (zh) * 2020-08-11 2022-02-22 南京柯菲平盛辉制药有限公司 五元杂环并苯环类化合物及其制备方法和医药用途
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN114394965B (zh) * 2021-01-29 2023-09-12 深圳市乐土生物医药有限公司 三唑并吡啶类化合物及其制备方法与用途
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN116354955A (zh) * 2021-12-28 2023-06-30 上海科胜药物研发有限公司 一种菲戈替尼的制备方法
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
US11596612B1 (en) 2022-03-08 2023-03-07 PTC Innovations, LLC Topical anesthetics
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A
CN116687925B (zh) * 2022-11-04 2024-10-22 中国科学院遗传与发育生物学研究所 一种侵蚀性蛋白酶抑制剂及其应用
LU505465B1 (en) * 2022-11-16 2024-05-14 Adlai Nortye Biopharma Co Ltd A pan-KRAS inhibitor compound
KR20260054550A (ko) * 2024-10-15 2026-04-22 한국화학연구원 JAK1를 선택적으로 저해하는 신규한 테트라하이드로이소퀴놀린 또는 이소인돌린 치환 [1,2,4]트리아졸로[1,5-a]피리딘 유도체 및 이의 용도
CN119462650B (zh) * 2024-11-20 2025-10-17 沈阳药科大学 一种非戈替尼的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156037B1 (en) * 1999-01-29 2004-12-01 Chugai Seiyaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
US20040138285A1 (en) 2001-04-27 2004-07-15 Makoto Okazaki Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
TWI221602B (en) * 2003-07-21 2004-10-01 Benq Corp Emergent disc-withdrawing apparatus
US20050222171A1 (en) * 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
EP1799680A2 (en) 2004-10-07 2007-06-27 Warner-Lambert Company LLC Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
JP5336375B2 (ja) * 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
ATE495743T1 (de) * 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
JP5352476B2 (ja) 2007-06-05 2013-11-27 武田薬品工業株式会社 キナーゼ阻害剤としての二環式複素環化合物
CN101801966A (zh) 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9088430B2 (en) * 2008-02-19 2015-07-21 Qualcomm Incorporated Providing network originated push messages for remotely testing a mobile device
US20090217316A1 (en) * 2008-02-22 2009-08-27 Binita Gupta Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
DE102009000543A1 (de) * 2009-02-02 2010-08-12 Evonik Degussa Gmbh Verfahren, Absorptionsmedien und Vorrichtung zur Absorption von CO2 aus Gasmischungen
JP5679995B2 (ja) * 2009-02-02 2015-03-04 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 酸性ガスの除去のための環式アミン含有吸収剤
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.

Similar Documents

Publication Publication Date Title
JP2011529032A5 (enExample)
JP7604006B2 (ja) Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法
US10246464B2 (en) Thienopyrimidine and thienopyridine compounds and methods of use thereof
JP2016525072A5 (enExample)
ES2987829T3 (es) Compuestos heterocíclicos para obtención de imágenes y tratamiento del cáncer y métodos para su uso
CR20220609A (es) Antagonistas del receptor de lpa y usos de los mismos
CN111542318A (zh) Ash1l降解剂及用其进行治疗的方法
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
MX2011008799A (es) Polipeptidos, dominios variables de anticuerpos, y antagonistas anti-tnfr1 mejorados.
TW200808314A (en) Treatment of chemokine mediated diseases
JP2017528498A (ja) Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
EA201000785A1 (ru) Композиции для доставки в легкие
UA100777C2 (ru) Вдыхаемые частички, содержащие тиотропий
NZ580009A (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
ATE495744T1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
JP2017518302A5 (enExample)
JP2016529218A5 (enExample)
US20230118233A1 (en) Prc1 inhibitors and methods of treatment therewith
PH12012500826A1 (en) Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP2012509279A5 (enExample)
JP2009541472A5 (enExample)
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
JP2017536397A5 (enExample)
EA201100422A1 (ru) (фенил)амиды 7-(пиперазин-1-илметил)-1h-индол-2-карбоновой кислоты и родственные соединения в качестве ингибиторов мар-киназы p38 для лечения заболеваний дыхательных путей
WO2008020269A3 (en) A method of treating tumors with azaxanthones